Can I Take Glycine with Prolia (Denosumab)?

What Denosumab (Prolia) Actually Does in Bone

Denosumab is a fully human monoclonal antibody that binds RANK ligand (RANKL), blocking the protein that normally activates osteoclasts. Without RANKL signaling, osteoclast differentiation slows, bone resorption falls, and net bone mineral density rises. In the key FREEDOM trial (N=7,868), denosumab 60 mg every 6 months reduced new vertebral fracture risk by 68% and hip fracture risk by 40% over 36 months versus placebo [1].

The FDA approved denosumab for postmenopausal osteoporosis in 2010, and the Endocrine Society clinical practice guideline recommends it as a first- or second-line agent for women with high fracture risk, particularly those who cannot tolerate oral bisphosphonates [2].

How Prolia Is Metabolized

Denosumab is a large-molecule biologic. It is not processed by cytochrome P450 enzymes, is not renally cleared in the usual sense, and does not interact with the drug transporters that govern most small-molecule drug-supplement collisions. The half-life averages 25 to 28 days after the 60 mg subcutaneous dose. Because denosumab avoids the CYP and P-gp pathways entirely, small molecules including amino acids consumed orally have essentially no opportunity to alter its absorption, distribution, or elimination.

Key Adverse Effects Worth Tracking

Hypocalcemia is the most clinically significant adverse effect. Denosumab suppresses bone resorption so effectively that calcium can drop, particularly in patients with vitamin D deficiency or renal impairment. The FDA label requires adequate calcium and vitamin D supplementation during therapy [3]. Any supplement that alters calcium or phosphorus metabolism deserves attention in this context, even if glycine itself does not directly affect serum calcium.

What Glycine Is and Why People Take It

Glycine is the simplest amino acid. The human body synthesizes roughly 3 g per day endogenously, but biosynthesis covers only about 20% of the estimated daily requirement of 15 g for collagen and glutathione production; the remainder comes from diet [4].

People supplement glycine for three main reasons: sleep quality, collagen support, and glycemic modulation. Each of these overlaps in a different way with the clinical picture of a patient on denosumab.

Glycine for Sleep

A randomized, placebo-controlled crossover trial by Bannai et al. (N=11) found that 3 g of glycine taken 1 hour before bed improved subjective sleep quality scores and reduced daytime sleepiness the following morning [5]. A second study by the same group (N=15) used polysomnography and showed glycine shortened time to sleep onset and increased slow-wave sleep without altering REM architecture [6]. The proposed mechanism involves glycine-induced lowering of core body temperature through peripheral vasodilation, not through direct sedation. This matters because poor sleep independently worsens bone remodeling markers in postmenopausal women, the same population most commonly treated with Prolia.

Glycine in Collagen Synthesis

Type-I collagen is the dominant structural protein of bone matrix. Every third residue in the collagen triple helix is glycine, making it the most abundant amino acid in collagen by molar fraction. A 2018 systematic review in Nutrients (N=805 across 8 trials) concluded that glycine-containing collagen hydrolysate supplementation, when combined with vitamin C, improved markers of bone collagen synthesis and reduced knee pain scores, though fracture endpoints were not measured [7]. No study has tested collagen peptides or isolated glycine alongside denosumab specifically.

Glycine and Blood Glucose

Glycine acts as an agonist at glycine-gated chloride channels in pancreatic beta cells, potentiating glucose-stimulated insulin secretion. A meta-analysis by Alves et al. Published in Diabetes & Metabolic Syndrome (2019, N=357 across 9 trials) found glycine supplementation reduced fasting glucose by a mean of 4.1 mg/dL (95% CI: 1.2 to 7.0) in people with type 2 diabetes or metabolic syndrome [8]. This mild glucose-lowering effect is generally benign, but patients on Prolia who also use insulin or sulfonylureas should be aware of additive hypoglycemic potential.

Is There a Direct Pharmacokinetic Interaction?

The short answer: no evidence supports one. Denosumab's biologic nature largely shields it from the small-molecule interactions that concern pharmacists when patients add oral supplements. No published pharmacokinetic study, case report, or drug interaction database entry (Natural Medicines, Lexicomp, or Micromedex as of 2025) lists a direct pharmacokinetic interaction between glycine and denosumab.

Why Amino Acids Rarely Conflict with Biologics

Monoclonal antibodies like denosumab are catabolized through the reticuloendothelial system, broken down into constituent amino acids, and recycled. Glycine is itself one of the amino acids produced when any protein, including denosumab, is degraded. Taking exogenous glycine does not increase or decrease the rate of denosumab catabolism. There is no shared transporter, no competitive binding site, and no enzymatic pathway where the two substances converge.

What the Natural Medicines Database Says

The Natural Medicines database rates the glycine-denosumab combination as having "no known interaction" as of the most recent update reviewed for this article. This classification reflects the absence of mechanistic overlap in pharmacokinetics rather than a definitive clinical safety study, since no such dedicated trial exists.

Pharmacodynamic Overlaps: The Real Conversation to Have

Even without a pharmacokinetic conflict, two agents can interact pharmacodynamically, meaning they affect the same physiological outcome through different pathways. Three areas warrant attention for glycine plus denosumab.

1. Bone Remodeling

Denosumab suppresses osteoclastic resorption. Glycine provides substrate for osteoblastic collagen synthesis. These actions are complementary rather than antagonistic. Conceptually, supporting collagen matrix while simultaneously reducing matrix breakdown is a sensible combination, though no clinical trial has tested dual outcomes in the same cohort. The FREEDOM extension study (10 years, N=2,626) showed sustained bone mineral density gains with continued denosumab [9], and a hypothetical adjunct that feeds the anabolic side of bone remodeling is biologically plausible, just not yet proven.

2. Glycemic Effects in Prolia Patients

Glucocorticoid-induced osteoporosis and type 2 diabetes frequently coexist. Some patients on Prolia also use antidiabetic medications. Glycine's modest insulin-secretion effect, roughly a 4 mg/dL reduction in fasting glucose, is unlikely to cause clinical hypoglycemia on its own. However, adding glycine to a regimen that already includes metformin, a GLP-1 agonist like semaglutide, or a sulfonylurea warrants a glucose check at 4 to 6 weeks. The effect size from the Alves meta-analysis is small enough that most clinicians would not adjust medication doses preemptively, but documentation in the chart is prudent.

3. Calcium Homeostasis

Glycine itself does not chelate calcium, unlike some other amino acids. No published study shows glycine supplementation at doses of 3 to 10 g/day altering serum calcium. This is reassuring given that hypocalcemia is the principal adverse effect of denosumab. Patients should still ensure baseline calcium intake of 1,000 to 1,200 mg/day and vitamin D3 intake of at least 800 IU/day per the National Osteoporosis Foundation guidelines, regardless of glycine use [10].

Dosing Considerations for People Taking Both

No evidence-based dose-separation window exists for glycine and denosumab. Because denosumab is given as a subcutaneous injection every 6 months, the concept of "take these 2 hours apart" simply does not apply. The two substances do not share a route of administration or an absorptive compartment.

Typical Glycine Doses and Their Context

• Sleep support: 3 g orally, 30 to 60 minutes before bedtime. This is the dose with the strongest randomized trial evidence [5].
• Collagen matrix support: 5 to 10 g/day as part of collagen hydrolysate or pure glycine powder, often taken with vitamin C to co-factor hydroxylation.
• Upper tolerable limit: No formal upper limit has been established by the Institute of Medicine. Doses up to 60 g/day have been studied in schizophrenia trials without serious adverse events [11].

A patient already receiving Prolia injections every 6 months at an infusion center or clinic may begin glycine at any point in the dosing cycle. The 6-month interval between Prolia doses does not create a window of particular vulnerability or safety.

What to Tell Your Prescriber

Clinicians should document glycine use in the medication reconciliation, flag it for the glycemic interaction if the patient uses hypoglycemics, and note it for renal-function review since glycine is an osmotic agent at high doses. Standard Prolia monitoring, including serum calcium at baseline, 2 weeks after the first injection, and then periodically, remains unchanged.

What the Evidence Does Not Tell Us

Several gaps remain in the literature. No randomized controlled trial has enrolled postmenopausal women on denosumab and randomized them to glycine versus placebo to measure bone mineral density, fracture rates, or adverse events. The collagen data cited above come from hydrolysate preparations containing multiple amino acids, not isolated glycine. Glycine's effect on RANKL expression in osteoblast cell lines has been studied in vitro (one 2021 paper in Amino Acids showed glycine at 10 mM suppressed RANKL mRNA in murine osteoblasts by approximately 18%) [12], but in vitro concentrations bear little resemblance to plasma concentrations achievable with oral supplementation.

The framework below organizes what we know by evidence tier and can serve as a clinical decision aid until direct clinical trial data exist.

Evidence tier for glycine plus denosumab:

| Domain | Evidence Level | Direction | Clinical Weight | |---|---|---|---| | Pharmacokinetic interaction | No interaction identified | Neutral | Low concern | | Bone collagen substrate support | Indirect (collagen trials, not denosumab-specific) | Potentially additive benefit | Moderate interest | | Glycemic effect | Randomized meta-analysis (small effect) | Mild glucose lowering | Monitor if on hypoglycemics | | Sleep improvement | Two small RCTs | Positive for sleep quality | Clinically relevant for bone health | | Calcium homeostasis | No interaction identified | Neutral | Low concern | | Hypocalcemia risk (Prolia-related) | FDA label black-box adjacent warning | Risk independent of glycine | Requires standard Prolia monitoring |

Monitoring Protocol for Patients Using Glycine with Prolia

A reasonable monitoring approach follows standard Prolia care with two small additions for glycine.

Standard Prolia Monitoring (Unchanged)

Serum calcium and vitamin D (25-OH) levels should be checked before each injection. Renal function (eGFR and serum creatinine) matters because denosumab can cause severe hypocalcemia in patients with CKD stage 4 or 5 [3]. Dental health review before starting therapy reduces osteonecrosis of the jaw risk.

Additional Monitoring for Glycine Use

Patients who use glycine at doses above 5 g/day and who also use insulin, a sulfonylurea, or a GLP-1 receptor agonist may benefit from a fasting glucose check at 4 to 6 weeks after starting glycine. One fasting glucose measurement is sufficient for most patients; continuous glucose monitoring is not required unless the patient is already using it. Patients using glycine solely for sleep at 3 g/night and who are not on hypoglycemics need no additional laboratory monitoring beyond standard Prolia protocol.

The American Association of Clinical Endocrinology (AACE) 2020 guideline on postmenopausal osteoporosis states: "Calcium and vitamin D supplementation should be provided to all patients receiving pharmacological osteoporosis therapy unless contraindicated, with monitoring of serum calcium and 25-hydroxyvitamin D levels." [13] Glycine does not alter this recommendation.

Special Populations

Patients with Chronic Kidney Disease

Denosumab requires dose adjustment awareness in CKD stages 4 and 5 because of elevated hypocalcemia risk. Glycine is an endogenous amino acid and does not accumulate in CKD to clinically meaningful levels at dietary or supplemental doses. However, very high glycine doses (above 20 g/day) have theoretical implications for oxalate metabolism since glycine is a precursor to oxalate. Patients with CKD and a history of calcium oxalate stones should keep glycine below 10 g/day and monitor urinary oxalate if concerned.

Postmenopausal Women with Diabetes

This is the highest-prevalence overlap group for Prolia use. Type 2 diabetes increases fracture risk independently of bone mineral density, and glycine's insulin-secretagogue properties are studied most in this population. The Alves 2019 meta-analysis specifically found the greatest glucose-lowering effect in patients with baseline fasting glucose above 110 mg/dL. For these patients, informing the endocrinologist and primary care provider about glycine use is appropriate before starting.

Patients on Concurrent Bone-Building Therapy

Some patients transition from denosumab to an anabolic agent like teriparatide (Forteo) or abaloparatide (Tymlos) or use romosozumab (Evenity) sequentially. Glycine's role as a collagen precursor is compatible with all of these mechanisms. No interaction data exist for the combination, and no contraindication is anticipated.

Practical Takeaway for Patients

Glycine is not contraindicated with Prolia. The evidence supports calling this a "no known pharmacokinetic interaction" pairing with minor pharmacodynamic overlap worth monitoring. Patients can start glycine at 3 g before bed for sleep, or up to 10 g/day for collagen support, without altering their Prolia injection schedule.

Three steps to take before starting:

1. Tell your prescribing physician or nurse practitioner that you plan to add glycine, the dose, and the reason. This allows documentation in your medication list.
2. If you use any diabetes medication, request a fasting glucose check 4 to 6 weeks after starting glycine.
3. Continue all standard Prolia monitoring: serum calcium, vitamin D, renal function, and dental review before each injection.

The FDA's GRAS classification for glycine covers food and supplement use at typical doses [14]. The agency has not issued any safety communication linking glycine to adverse outcomes with RANK ligand inhibitors.